Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Endonovo Therapeutics (ENDV) Cash & Equivalents (2016 - 2023)

Endonovo Therapeutics has reported Cash & Equivalents over the past 13 years, most recently at $32602.0 for Q2 2023.

  • Quarterly results put Cash & Equivalents at $32602.0 for Q2 2023, changed N/A from a year ago — trailing twelve months through Jun 2023 was $32602.0 (changed N/A YoY), and the annual figure for FY2022 was $98.0, down 99.89%.
  • Cash & Equivalents for Q2 2023 was $32602.0 at Endonovo Therapeutics, up from $10942.0 in the prior quarter.
  • Over the last five years, Cash & Equivalents for ENDV hit a ceiling of $547530.0 in Q2 2019 and a floor of $98.0 in Q4 2022.
  • Median Cash & Equivalents over the past 5 years was $13420.0 (2020), compared with a mean of $56724.4.
  • Biggest five-year swings in Cash & Equivalents: surged 48198.88% in 2021 and later tumbled 99.89% in 2022.
  • Endonovo Therapeutics' Cash & Equivalents stood at $18893.0 in 2019, then decreased by 28.97% to $13420.0 in 2020, then skyrocketed by 540.36% to $85936.0 in 2021, then tumbled by 99.89% to $98.0 in 2022, then soared by 33167.35% to $32602.0 in 2023.
  • The last three reported values for Cash & Equivalents were $32602.0 (Q2 2023), $10942.0 (Q1 2023), and $98.0 (Q4 2022) per Business Quant data.